TCT 2021 | Long-term follow-up of a “fast-DC” immunotherapy as a post-remission strategy for AML
Yngvar Fløisand
• 11 Feb 2021
Yngvar Floisand, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the long-term follow-up results of dendritic cell (DC) immunotherapy targeting PRAME and WT-1 as a post-remission strategy in patients with acute myeloid leukemia (AML). The findings suggest that immunotherapy with autologous DC transfected with PRAME and WT-1 RNA is safe and feasible, whilst demonstrating encouraging long-term progression-free survival and overall survival. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
